| 000 | 01054 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250515004306.0 | ||
| 264 | 0 | _c20060119 | |
| 008 | 200601s 0 0 eng d | ||
| 022 | _a1047-2797 | ||
| 024 | 7 |
_a10.1016/j.annepidem.2005.04.012 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMirer, Franklin E | |
| 245 | 0 | 0 |
_aComment on Caprolactam study. _h[electronic resource] |
| 260 |
_bAnnals of epidemiology _cNov 2005 |
||
| 300 |
_a735; author reply 736 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_aBenzene _xadverse effects |
| 650 | 0 | 4 | _aCaprolactam |
| 650 | 0 | 4 | _aChemical Industry |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia _xchemically induced |
| 650 | 0 | 4 | _aNetherlands |
| 650 | 0 | 4 | _aOccupational Exposure |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 | _aRisk Assessment |
| 773 | 0 |
_tAnnals of epidemiology _gvol. 15 _gno. 10 _gp. 735; author reply 736 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.annepidem.2005.04.012 _zAvailable from publisher's website |
| 999 |
_c15884252 _d15884252 |
||